Premium
Aripiprazole: A treatment for severe coprolalia in “refractory” Gilles de la Tourette syndrome
Author(s) -
Ben Djebara Mouna,
Worbe Yulia,
Schüpbach Michael,
Hartmann Andreas
Publication year - 2007
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.21859
Subject(s) - aripiprazole , tourette syndrome , psychology , psychotherapist , psychiatry , refractory (planetary science) , tourette's syndrome , psychoanalysis , schizophrenia (object oriented programming) , physics , astrobiology
Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28‐year‐old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics. © 2007 Movement Disorder Society